Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.40 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21964546 | 0.77 | L3MBTL1 (0.43) | POLBILKSYKKEAP1SMN1; SMN2 | |
| SCHEMBL23880184 | 0.77 | POLB (0.41) | POLBSIGMAR1SYKKCNH2 | |
| SCHEMBL16061204 | 0.76 | POLB (0.45) | POLBSMN1; SMN2MAPT | |
| SCHEMBL21960902 | 0.75 | POLB (0.67) | POLBSMN1; SMN2MAPT | |
| SCHEMBL16985426 | 0.74 | MAPT (0.43) | SIGMAR1ILKKEAP1SMN1; SMN2MAPT | |
| SCHEMBL8374733 | 0.73 | ADORA2A (0.44) | MAPT | |
| SCHEMBL21961356 | 0.73 | PDE8B (0.39) | MAPT | |
| SCHEMBL19615359 | 0.72 | POLB (0.47) | POLB | |
| SCHEMBL19557911 | 0.72 | GLS (0.41) | SMN1; SMN2MAPT | |
| SCHEMBL2428069 | 0.72 | GLS (0.41) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | POLB 2998/4885SIGMAR1 3330/4885ILK 4037/4885 |
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | POLB 1088/4885SIGMAR1 3838/4885ILK 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.